key: cord-0928109-2p4wt7ko authors: Cortellini, Alessio; Salazar, Ramon; Gennari, Alessandra; Aguilar-Company, Juan; Bower, Mark; Bertuzzi, Alexia; Brunet, Joan; Lambertini, Matteo; Maluquer, Clara; Pedrazzoli, Paolo; Lee, Alvin JX.; Carmona-García, MCarmen; Newsom-Davis, Thomas; Van Hemelrijck, Mieke; Plaja, Andrea; Zambelli, Alberto; Tondini, Carlo; Generali, Daniele; Bertulli, Rossella; Diamantis, Nikolaos; Mukherjee, Uma; Rizzo, Gianpiero; Yu, Tamara; Zoratto, Federica; Bruna, Riccardo; Sureda, Anna; Martinez-Vila, Clara; Cantini, Luca; Mazzoni, Francesca; Grosso, Federica; Parisi, Alessandro; Saponara, Maristella; Prat, Aleix; Pinato, David J. title: Persistence of long-term COVID-19 sequelae in patients with cancer: an analysis from the OnCovid registry. date: 2022-04-26 journal: Eur J Cancer DOI: 10.1016/j.ejca.2022.03.019 sha: 45640c3d41484c1ed903c58488fadc75804a7b63 doc_id: 928109 cord_uid: 2p4wt7ko INTRODUCTION: A significant proportion of patients with cancer who recover from COVID-19 may experience COVID-19 sequelae in the early post-infection phase, which negatively affect the continuity of care and oncological outcome. The long-term prevalence and clinical impact of post-COVID-19 syndrome in patients with cancer are largely unknown. METHODS: In this study, we describe the time course of COVID-19 sequelae in patients with non-advanced cancers enrolled into the OnCovid registry. RESULTS: Overall, 186 patients were included, with a median observation period of 9.9 months (95%CI:8,8-11.3) post COVID-19 resolution. After a median interval of 2.3 months post-COVID-19 (interquartile range: 1.4-3.7), 31 patients (16.6%) reported >1 sequelae, including respiratory complications (14, 7.6%), fatigue (13, 7.1%), neuro-cognitive sequelae (7, 3.8%). The vast majority of the patients were not vaccinated prior to COVID-19. COVID-19-related sequelae persisted in 9.8% and 8% of patients 6 and 12 months after COVID-19 resolution. Persistence of sequelae at first oncological follow-up was associated with history of complicated COVID-19 (45.2% vs 24.8%, p=0.0223), irrespective of oncological features at COVID-19 diagnosis. CONCLUSION: This study confirms for the first time that, in a largely unvaccinated population, post-COVID-19 syndrome can affect a significant proportion of patients with non-advanced cancer who recovered from the acute illness. COVID-19 sequelae may persist up to 12 months in some patients, highlighting the need for dedicated prevention and supportive strategies. A significant proportion of Coronavirus Disease 2019 survivors are at risk of developing post-COVID-19 syndrome 1 , a complex manifestation of likely immuneinflammatory pathogenesis that is characterized by a wide variety of symptoms including persistent fatigue, neuro-cognitive sequelae and varying degrees respiratory impairment. Evidence in non-cancer populations suggests chronic consequences from COVID-19 to persist beyond 6 months post-infection 2,3 . Patients with cancer are especially vulnerable to COVID-19 [4] [5] [6] , and recent evidence from the OnCovid study suggests that at least 15% of those who outlive the acute phase of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection can experience COVID-19 sequelae, which significantly affect the continuity of their oncological care and survival outcome, independent of oncological prognostic factors 7 . There is no evidence to suggest whether post-COVID-19 syndrome can lead to longterm consequences in patients with cancer. In this study, we evaluated OnCovid registry participants with non-advanced cancer, to estimate prevalence, duration and clinical significance of long-term sequelae from COVID-19. OnCovid (NCT04393974) is an active European registry study that, since the beginning of the pandemic, has collected consecutive patients fulfilling the following inclusion criteria: 1) age ≥18 years; 2) diagnosis of SARS-CoV-2 infection confirmed by RT-PCR of a nasopharyngeal swab; 3) history of solid or hematologic malignancy, at any time during the patients' past medical history, either active or in remission at the time of COVID-19 diagnosis. By the data lock of 22nd of December 2021, the registry included 3237 consecutive patients from 36 institutions across 6 countries (UK, Italy, Spain, France, Belgium and Germany), and included patients diagnosed with COVID-19 between the 27th of February 2020 and the 30th of November 2021. A list of the participating centers with eligible patients for this analysis is provided in Supplementary Table 1 . We evaluated long-term outcomes in patients with non-advanced cancer who had The eligible study population consisted of 3108 patients. After the exclusion of patients with advanced/metastatic disease and those who had not undergone a 6-months reassessment and those who experienced SARS-CoV-2 re-infection during follow-up, 186 patients were included in this analysis (Figure 1 ). The first reassessment was performed as per local practice, with a median interval of (Figure 2A) . Disease progression at 6-months was reported for 9 patients among those experiencing sequelae (50%) and for 54 (32.5%) among those who did not experienced sequelae (p=0.1390). Data on oncological follow up at 12-months was available for 100 patients; among them 8 (8%) experienced COVID-19 sequelae and 2 patients (2%), multiple-sites sequelae. In detail, 3 patients (3%) reported respiratory sequelae, 3 (3%) post COVID-19 fatigue (Figure 2A) . Disease progression at 12-months was reported for 5 patients and 39 patients in the sequelae and non-sequelae subgroups, respectively (62.5% vs 42.4%, p=0.2951). In the context of a progressive improvement in terms of disease management, hospital/testing capacity, and vaccinal campaigns 9 , post-COVID syndrome continues to pose a threat to the wellbeing of patients with cancer. Although including only patients with non-advanced tumours, with a likely lower burden of cancer-related symptoms, this study confirms our previous findings in unselected patients with cancer 10 OnCovid is sponsored by Imperial College London and received direct project funding and infrastructural support by the NIHR Imperial Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Neither sponsor nor the funders of the study had any role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had access to all the data reported in the study. The data underlying this article cannot be shared publicly in accordance with current regulations on data protection. The data will be shared on reasonable request to the corresponding author. OnCovid was granted central approval by the United Kingdom Health Research Authority (20/HRA/1608) and by the corresponding research ethics committees at each participating institution. Full waiver of consent due to the retrospective nature of the study was granted by the UK HRA in accordance with UK law. . Figure 1 : study flow diagram. Figure 2 : prevalence of COVID-19 sequelae. A) Prevalence at the first clinical reassessment (31/184: 16%), at 6-months (18/184: 9.8%), and at 12-months (8/100: 8%). Type of sequelae at the first reassessment: respiratory sequelae (14: 7.6%), fatigue (13: 7.1%), neuro-cognitive sequelae (7: 3.8%), others (7: 3.8%). Type of sequelae at the 6-months reassessment: respiratory sequelae (9: 4.9%), fatigue (6: 3.2%), neuro-cognitive sequelae (4: 2.2%), others (5: 2.7%). Type of sequelae at the 12-months reassessment: respiratory sequelae (3: 3%), fatigue (3: 3%), neurocognitive sequelae (1: 1%), others (3: 3%). B) Prevalence of COVID-19 sequelae at the first reassessment among never smokers (8/83: 9.6%), current/former smokers (17/64: 26.6%), and among patients who did not experience prior complications from COVID-19 (17/132: 12.9%), and those who experienced complicated COVID-19 (14/52: 26.9%). J o u r n a l P r e -p r o o f Long COVID and Postinfective Fatigue Syndrome: A Review The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. The Lancet Oncology Post COVID-19 condition Clinical case definition Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study Acute Neurological Complications of COVID-19 Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study Months After COVID-19 Infection Attributes and predictors of long COVID Characteristics of Adult Outpatients and Inpatients with COVID-19 -11 Academic Medical Centers OnCovid received direct project funding and infrastructural support by the NIHR Imperial Biomedical Research Centre (BRC). Alessio Cortellini is supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC